Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design
- 1 May 2007
- journal article
- immunological monitoring-and-immunotherapy
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 2 (3) , 183-188
- https://doi.org/10.1097/coh.0b013e3280f3bfe2
Abstract
Purpose of review HIV diversity is a major challenge to accurate detection of HIV-specific immunity in vitro and HIV vaccine immunogen design alike. Although achieving extensive coverage of global viral diversity is a common goal for both tasks, different strategies for achieving maximal in-vitro detection of responses and optimal in-vivo induction of immune responses may be needed. This review describes and compares some of the most recently developed approaches. Recent findings Single sequence-based antigen sets as well as polyvalent peptide test reagents have been developed over recent years that are suitable for detection of comprehensive CD4+ and CD8+ T-cell immunity in the naturally infected or vaccinated host. These tools permit increasingly accurate assessment of the host immune response, thus providing the basis for identification of immune correlates of controlled HIV infection. Summary These recent findings and newly developed strategies that allow more comprehensive detection of HIV-specific T-cell responses provide the tools necessary to assess vaccine immunogenicity and breadth within genetically different host populations and relative to diverse local viral populations. They will ultimately inform design of vaccine immunogen sequences that can induce broadly protective cellular immunity.Keywords
This publication has 32 references indexed in Scilit:
- Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluationVaccine, 2006
- Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env ImmunogenJournal of Virology, 2006
- Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trialJournal of General Virology, 2006
- Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopesNature Immunology, 2005
- Fluorescent Antigen–Transfected Target Cell Cytotoxic T Lymphocyte Assay for Ex Vivo Detection of Antigen‐Specific Cell‐Mediated CytotoxicityThe Journal of Infectious Diseases, 2005
- The Majority of Currently Circulating Human Immunodeficiency Virus Type 1 Clade B Viruses Fail To Prime Cytotoxic T-Lymphocyte Responses against an Otherwise Immunodominant HLA-A2-Restricted Epitope: Implications for Vaccine DesignJournal of Virology, 2005
- Discovery and characterization of highly immunogenic and broadly recognized mimics of the HIV‐1 CTL epitope Gag77–85European Journal of Immunology, 2005
- Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple EthnicitiesJournal of Virology, 2004
- Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variantsNature, 1994
- HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptidesNature, 1988